Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs BMRN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMRN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

BMRN Overall Winner 6-Pillar Tally: IONS 2 – 4 BMRN Matrix Metrics: IONS 2 – 8 BMRN

As of Nov 16, 2026, BioMarin Pharmaceuticals Inc (BMRN) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas BMRN carries 52.6/100 (HOLD) at $58.32 (9.1x Forward P/E, 16.3% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. BMRN 52.6/100 HOLD), BMRN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (16.3% vs. -58.8% operating margin) and revenue trajectory (+32.0% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile BMRN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs BMRN
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
BMRN NASDAQ Head-to-Head Winner
BioMarin Pharmaceuticals Inc
Pharmaceutical Preparations
$58.32
+1.9% 1D
Market Cap $11.0B
TTM Revenue $3.66B
Forward P/E 9.1x
Beta / 30D Vol 0.28β · 31% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 57.0 Fund 61.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.0 · SMA20: $56.73 · SMA50: $58.69

6-Pillar Scorecard Institutional Category Breakdown (IONS 2 – 4 BMRN)

Columns: Metric · IONS · BMRN
1. Valuation Multiples BMRN
Forward P/E 90.9x 9.1x
Trailing P/E 90.9x 8.8x
PEG Ratio N/M 0.34x
EV / Revenue 6.2x 3.9x
2. Growth & Scale IONS
Revenue Growth (YoY) +54.9% +32.0%
Earnings Growth (YoY) -43.7% -81.3%
TTM Revenue (USD) $960M $3.66B
Market Cap $4.7B $11.0B
3. Profitability & Quality BMRN
Gross Margin 3.0% 53.2%
Operating Margin -58.8% 16.3%
Net Profit Margin -56.9% -0.5%
Return on Equity (ROE) -108.0% -0.3%
4. Balance Sheet & Cash Flow BMRN
Cash Generation (TTM) -$623M $554M
Cash Flow Margin -64.9% 15.2%
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $3.45B Net Debt (0.67x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BMRN
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 59.9% (17th %ile) 37.4% (17th %ile)
Put/Call OI Skew 1.81x (Put-Skewed) 0.06x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 61.8% of Rev ($593M) 36.9% of Rev ($1.35B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (2) vs BMRN (8)
Institutional Metric IONS BMRN Criterion Row Edge
Market Capitalization
Scale
$4.7B $11.0B Larger Scale BMRN
Trailing P/E Ratio
Valuation
90.9x 8.8x Lower Multiple BMRN
Forward P/E Ratio
Valuation
90.9x 9.1x Lower Multiple BMRN
Revenue Growth (YoY)
Growth
+54.9% +32.0% Higher Growth IONS
Operating Margin (TTM)
Profitability
-58.8% 16.3% Higher Margin BMRN
Net Profit Margin
Profitability
-56.9% -0.5% Higher Margin BMRN
Return on Equity (ROE)
Capital Efficiency
-108.0% -0.3% Higher ROE BMRN
52-Week Range Position
Momentum
2% ($27–$87) 42% ($49–$71) Stronger Trend BMRN
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 0.28β · 31% Vol Lower Realized Risk BMRN
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 52.6 / 100 (HOLD) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M $3.66B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% 53.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev 0.34x PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) $554M ($3.45B Net Debt (0.67x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BMRN +40.14 pp
IONS: -33.48% · BMRN: +6.66%
3M Horizon BMRN +39.15 pp
IONS: -52.09% · BMRN: -12.94%
6M Horizon BMRN +78.02 pp
IONS: -60.61% · BMRN: +17.41%
1Y Horizon BMRN +66.66 pp
IONS: -59.1% · BMRN: +7.56%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IONS Revenue BMRN Revenue IONS Op. Margin BMRN Op. Margin Margin Leader
FY2018 $600M $1.49B -10.2% -8.3% BMRN
FY2019 $1.12B $1.70B 32.6% -5.9% IONS
FY2020 $730M $1.86B -23.6% -2.3% BMRN
FY2021 $810M $1.85B -3.7% -4.5% IONS
FY2022 $590M $2.10B -69.8% 7.7% BMRN
FY2023 $790M $2.42B -44.9% 7.7% BMRN
FY2024 $710M $2.85B -67.4% 17.0% BMRN
FY2025 $940M $3.22B -40.4% 12.7% BMRN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRN CONSOLIDATION
67d in phase · OBV DISTRIBUTION
Current IV 37.4%
IV Percentile 17th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BMRN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
BMRN Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $11.0B market capitalization and 16.3% operating margin.
OpEx & R&D Reinvestment 36.9% of Rev ($1.35B)
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs BMRN Key Questions & Quantitative Answers

As of Nov 16, 2026, BioMarin Pharmaceuticals Inc (BMRN) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas BMRN carries 52.6/100 (HOLD) at $58.32 (9.1x Forward P/E, 16.3% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. BMRN 52.6/100 HOLD), BMRN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (16.3% vs. -58.8% operating margin) and revenue trajectory (+32.0% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile BMRN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IONS leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with BMRN at +32.0% YoY revenue growth and -81.3% YoY earnings growth on $3.66B TTM revenue (53.2% gross margin, 16.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IONS cumulative revenue shifted +56.7% while BMRN shifted +116.1%. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 36.9% of Rev ($1.35B) (0 disclosures) for BMRN.

BMRN screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas BMRN trades at 9.1x Forward P/E, 8.8x Trailing P/E, 0.34x PEG, and 3.9x EV/Revenue (15.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus BMRN (-0.3% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, BMRN carries 37.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.